NeoGenomics, Inc. (NEO)

NeoGenomics' stock price has experienced fluctuations in the past six months. Key events impacting the stock price include the Q2 2025 earnings report, which missed revenue expectations, and the launch of PanTracer LBx. A court ruled in favor of NeoGenomics in a patent infringement lawsuit against Natera. The Q3 2025 earnings report surpassed revenue estimates, driven by clinical testing growth. NeoGenomics presented its RaDaR ST Bridging Study at ISLB 2025 and participated in investor conferences. Analysts project a potential upside of 13.41% based on an average target price of $13.17, with a consensus rating of "Hold."

Demand seasonality for NeoGenomics, Inc.'s products and services is not as directly affected by typical seasonal patterns as some other industries. The volume of testing for their pharmaceutical development services can vary based on the terms of individual contracts. Severe weather events could potentially reduce revenues and cash flows in affected periods. The company's annualized revenue growth has been stable, suggesting consistent demand, and analysts anticipate continued revenue growth.

NeoGenomics, Inc. is a global provider of cancer-focused genetic testing solutions and information services, operating in the Healthcare sector, specifically in the Medical Diagnostics & Research industry. The company offers a comprehensive oncology-focused testing menu for physicians and supports pharmaceutical clients in clinical trials and drug development. Major products and services include genomic testing such as NGS, FISH, and IHC, encompassing cytogenetics, flow cytometry, anatomic pathology, and molecular genetics. NeoGenomics focuses on various therapeutic areas and cancer types, including lung, breast, colorectal, and blood cancers, and provides specialized pharma services like biomarker development, clinical trial testing, and data analysis. Recent product launches include PanTracer Liquid Biopsy (LBx) and PanTracer Tissue.

NeoGenomics has a global geographic footprint with its headquarters in Fort Myers, Florida, USA. The company operates CAP accredited and CLIA certified laboratories in multiple US locations, including Florida, California, North Carolina, Texas, Georgia, Tennessee, and Arizona. Internationally, NeoGenomics has CAP accredited laboratories and offices in Europe (Cambridge, United Kingdom, and Rolle, Switzerland) and Asia-Pacific (Singapore, with China operations through partnerships/subsidiaries in Suzhou).

NeoGenomics has actively focused on enhancing its brand reputation through corporate social responsibility and ethical practices. The company released its inaugural ESG Report in March 2024, highlighting progress toward building a sustainable, diverse, and equitable company. In August 2025, NeoGenomics published its CSR report for 2024 and into 2025, reiterating its mission to improve patient care and democratize precision medicine. The 2024 Employee Engagement Survey showed improvements in 27 out of 31 metrics. No significant negative events specifically impacting NeoGenomics' brand reputation within the past year were prominently found.

NeoGenomics has a mixed ownership structure, with institutional investors holding a significant portion. Approximately 84.48% of the company's stock is owned by Institutional Investors, 1.22% by Insiders, and 14.30% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and First Light Asset Management, LLC. Notable individual or insider owners include Electric Co General, Peter M. Peterson, Steven C. Jones, and Michael T. Dent.